Tesamorelin vs Semaglutide

TL;DR

- Tesamorelin is a GHRH analog studied for visceral fat. In a phase 3 trial it reduced visceral adipose tissue by about 15.2 percent versus placebo (Falutz et al., 2007). - Semaglutide is a GLP-1 receptor agonist studied for total body weight. In STEP 1, participants lost about 15 percent of body weight, roughly 15.3 kg mean (Wilding et al., 2021). - The two work through opposite pathways: tesamorelin acts on the growth hormone axis, semaglutide acts on appetite and satiety signaling. - Fat compartment studied differs: tesamorelin trials measured visceral adipose tissue specifically, semaglutide trials measured total body weight. The trial populations also differ, so the percentages are not a head-to-head comparison. - Neither is a self-directed protocol. Dose ranges below are what trials reported, not instructions. A qualified clinician decides any personal use.

What is the core difference between tesamorelin and semaglutide?

They target fat through opposite mechanisms: tesamorelin stimulates growth hormone release to reduce visceral fat, while semaglutide mimics GLP-1 to reduce appetite and total body weight.

Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH). It signals the pituitary to release the body's own growth hormone, which in turn affects fat metabolism. In its phase 3 program, tesamorelin lowered visceral adipose tissue by about 15.2 percent compared with placebo (Falutz et al., 2007). It carries an approved indication (marketed as Egrifta) for reducing excess visceral abdominal fat in a specific patient population.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It slows gastric emptying and acts on appetite centers, which lowers food intake. In the STEP 1 trial, participants on semaglutide lost about 15 percent of body weight, a mean of roughly 15.3 kg, versus placebo (Wilding et al., 2021).

The short version: one raises a growth-axis signal to shift visceral fat, the other quiets hunger to shift overall weight.

How do tesamorelin and semaglutide compare side by side?

Tesamorelin was studied against a visceral fat endpoint, semaglutide against a total body weight endpoint, so their trial results are not directly interchangeable.

What dose ranges did the trials report?

In the published trials, participants received fixed regimens set by the study protocol, not a personalized dose. What follows describes trial design only. Your personal dose is a clinician's decision.

These figures are reported from the named trials. They are not a recommendation, a starting point, or a schedule. Route any decision about use to a qualified clinician.

What about half-life and dosing frequency?

Tesamorelin was studied as a daily injection, while semaglutide was studied as a once-weekly injection, reflecting different pharmacokinetics.

Tesamorelin has a short circulating half-life and was dosed daily in its trial program (Falutz et al., 2007). Semaglutide has a long half-life that supports once-weekly dosing, which is how it was given in STEP 1 (Wilding et al., 2021). This is one of the clearest practical contrasts between the two: frequency of administration in the studies.

Which one is the right comparison for a given research question?

It depends on the endpoint: tesamorelin trials answer a visceral fat question, semaglutide trials answer a total body weight question.

If the research interest is specifically visceral adipose tissue, the tesamorelin literature is the direct match, since its phase 3 endpoint was VAT reduction of about 15.2 percent (Falutz et al., 2007). If the interest is overall body weight change, the semaglutide literature is the direct match, with about 15 percent mean loss in STEP 1 (Wilding et al., 2021).

They are not competitors on the same endpoint. One outcome that matters across both: semaglutide trials show meaningful weight regain after the drug is stopped (Wilding et al., 2022), a durability question the tesamorelin primary trial was not designed to answer. Any comparison for a personal situation belongs with a qualified clinician who can weigh mechanism, indication, and safety.